Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review

Date: April 19, 2017
Pages: 79
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B9BD9859156EN
Leaflet:

Download PDF Leaflet

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review
Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indications. The company's product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter - OTC) products, seeds, crop protection solutions, nonagricultural pest control solutions, and high-tech polymer materials. Bayer markets its healthcare and crop protection products principally through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, the US, and other markets such as Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG Key Recent Developments

Mar 22,2017: Bayer to Showcase Data on Growing Oncology Pipeline at AACR 2017
Feb 22,2017: Another record year for Bayer – good progress with the acquisition of Monsanto
Feb 14,2017: Bayer Thrombosis Research Award 2017 goes to Dr. David Seiffge
Jan 17,2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region
Dec 12,2016: Robert LaCaze to be Executive Vice President of New Oncology Strategic Business Unit at Pharmaceuticals Division of Bayer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Bayer AG - Key Facts
Bayer AG - Key Employees
Bayer AG - Key Employee Biographies
Bayer AG - Major Products and Services
Bayer AG - Pharmaceutical Pipeline Products Data
Bayer AG, Pipeline Products by Therapy Area
Bayer AG, Pipeline Products by Development Phase
Bayer AG - History
Bayer AG - Company Statement
Bayer AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Bayer AG - Business Description
Bayer AG - Corporate Strategy
Bayer AG - SWOT Analysis
SWOT Analysis - Overview
Bayer AG - Strengths
Bayer AG - Weaknesses
Bayer AG - Opportunities
Bayer AG - Threats
Bayer AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Bayer AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Bayer AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 22, 2017: Bayer to Showcase Data on Growing Oncology Pipeline at AACR 2017
Feb 22, 2017: Another record year for Bayer – good progress with the acquisition of Monsanto
Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region
Dec 12, 2016: Robert LaCaze to be Executive Vice President of New Oncology Strategic Business Unit at Pharmaceuticals Division of Bayer
Nov 13, 2016: New landmark study reveals adults with diabetes at unnecessary risk of vision loss
Oct 25, 2016: Phlexglobal provides a global consolidated eTMF solution for Bayer
Oct 17, 2016: Bayer Early Excellence in Science Award 2016: EUR 30,000 for international research scientists
Sep 20, 2016: Bayer sets ambitious growth and earnings aspirations
Aug 10, 2016: Bayer: Prevalence of life-threatening neural tube defects on the rise
Aug 04, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Bayer AG, Key Facts
Bayer AG, Key Employees
Bayer AG, Key Employee Biographies
Bayer AG, Major Products and Services
Bayer AG, Number of Pipeline Products by Therapy Area
Bayer AG, Number of Pipeline Products by Development Stage
Bayer AG, History
Bayer AG, Subsidiaries
Bayer AG, Joint Venture
Bayer AG, Key Competitors
Bayer AG, Ratios based on current share price
Bayer AG, Annual Ratios
Bayer AG, Annual Ratios (Cont.1)
Bayer AG, Annual Ratios (Cont.2)
Bayer AG, Interim Ratios
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Bayer AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Bayer AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Bayer AG, Pipeline Products by Therapy Area
Bayer AG, Pipeline Products by Development Phase
Bayer AG, Performance Chart (2012 - 2016)
Bayer AG, Ratio Charts
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Pfizer Inc
Novartis AG
Mitsubishi Chemical Corporation
Johnson & Johnson
Huntsman Corporation
Heska Corp
GlaxoSmithKline Plc
BASF SE
Allergan Plc
Skip to top


Ask Your Question

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: